In Poland, Next-Generation Sequencing (NGS) availability is hindered by equipment costs, limiting its use to comprehensive cancer centers. Molecular Tumor Boards convene monthly, aiding personalized cancer treatments based on genomic insights.

However, Poland faces challenges in education and reimbursement for NGS/Liquid Biopsy, along with a shortage of trained personnel. Labs lack ISO accreditation, and there’s no external quality assessment for NGS testing, impacting standardized practices. Shortages in the healthcare workforce and limited data sharing highlight areas needing attention for better cancer care and research in Poland. Addressing education, workforce, and standardization gaps could vastly improve NGS utilization.

For comprehensive insights, refer to the factsheet below.